

Amendments to the Claims

This listing of claims will replace all prior versions and listing of claims in the application.

Claims 1-2 (Canceled)

3. (Original) The salt (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate.

4. (Previously presented) The salt according to claim 3 in crystalline form.

5. (Previously presented) A pharmaceutical formulation containing, as active ingredient, the salt according to claim 3 or 4 in association with a suitable diluent, excipient or an inert carrier.

Claims 6-11 (Canceled)

12. (Currently amended) A method for the [prevention or the] treatment of a condition selected from the group consisting of depression and anxiety [CNS disorders and related medical disturbances] comprising administration, to a host in need of such treatment, an effective amount of the salt according to claim 3 or 4.

13. (Cancelled)

14. (Currently amended) The [A] method according to claim 12, wherein the condition is [+] depression.

15. (Currently amended) The [A] method according to claim 12, wherein the condition is [13
for the prevention or the treatment of] anxiety.

16. (Currently amended) A process of making the salt as defined in claim 3 or 4 which comprises the following consecutive steps:

- i) dissolving (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide in an organic [appropriate] solvent, optionally by heating,
- ii) adding (2R, 3R)-tartaric acid dissolved in an [appropriate] aqueous organic solvent or non-aqueous organic solvent,
- iii) allowing the solution obtained to stand cold to crystallize,
- iv) optionally recrystallizing in an [appropriate] aqueous organic solvent, if a non-aqueous organic solvent is used in step ii),

to obtain the salt defined in any one of claims 3 or 4.

17. (Currently amended) A process of making the salt as defined in claims 3 to 4 which comprises [a final step of] recrystallizing (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-benzopyran-5-carboxamide hydrogen (2R, 3R)-tartrate in an [appropriate] aqueous organic solvent.

18. (Currently amended). The [A] process according to claim 16 or 17, wherein the aqueous organic solvent is aqueous acetone.

Claims 19-20 (Cancelled)

21. (Currently amended) The [A] pharmaceutical formulation according to claim 5, wherein the pharmaceutical formulation is an oral dosage form [for oral administration].

Claims 22-43 (Cancel)

44. (Currently amended) The pharmaceutical formulation according to claim 5 further comprising [Claim 42] a lubricant.

Claims 45-54 (Cancelled)